

# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road,  
Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150

Fax: 00 91 (22) 2202 4657 E-mail: [info@amphray.com](mailto:info@amphray.com)

Website: [www.triochemproducts.com](http://www.triochemproducts.com) Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20211232 2021; 12<sup>th</sup> February 2022

To

BSE Limited

Corporate Relationship Department,

Phiroze Jeejeebhoy Towers, Dalal Street,

Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Submission of Unaudited Financial Results for the Quarter and Nine Months ended 31<sup>st</sup> December 2021

We refer to our letter dated 30<sup>th</sup> December 2021 on the captioned subject.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this subject, we wish to inform you that the Board of Director of the Company at its meeting held today i.e. Saturday, 12<sup>th</sup> February, 2022 have inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2021 duly reviewed by the Audit Committee.

The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report are enclosed for your perusal and records.

Also, informed that the audited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in you record.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA  
DIRECTOR & CEO  
DIN: 00312369  
Encl.: as above



**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")**

1. We have reviewed the accompanying statement of unaudited financial results of **TRIOCHEM PRODUCTS LIMITED ("Company")** for the quarter and nine months ended December 31, 2021 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
2. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP  
Chartered Accountants  
Firm Registration No: 104746W/W100096

KUNAL  
SUMANTBHAI  
VAKHARIA

Digitally signed by KUNAL  
SUMANTBHAI VAKHARIA  
Date: 2022.02.12 14:17:54  
+05'30'

Kunal Vakharia  
Partner  
Membership No.: 148916  
UDIN: 22148916ABNPDJ3681



Place: Mumbai  
Date: 12<sup>th</sup> February 2022



**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,  
PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544

**TRIOCHEM PRODUCTS LIMITED**

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: [www.triochemproducts.com](http://www.triochemproducts.com)

CIN : L24249MH1972PLC015544

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021**

(Rs in Lakh) Except EPS

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-21 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Mar-21 (Audited)
1	<b>Income</b>						
	(a) Revenue from Operations	311.25	326.27	394.50	637.52	620.36	1,393.84
	(b) Other Income	3.85	11.00	0.16	33.04	5.84	13.38
	<b>Total Income From Operations</b>	<b>315.10</b>	<b>337.27</b>	<b>394.66</b>	<b>670.56</b>	<b>626.20</b>	<b>1,407.22</b>
2	<b>Expenses</b>						
	(a) Cost of Materials Consumed	0.02	-	-	0.02	644.54	644.87
	(b) Purchase of stock in trade	0.87	549.75	-	550.62	-	602.73
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	203.61	(274.87)	360.19	(71.26)	(111.88)	13.41
	(d) Employees Benefit Expenses	15.25	12.78	16.74	39.53	50.52	66.91
	(e) Finance Costs	-	1.14	2.47	1.52	9.53	10.90
	(f) Depreciation and Amortisation Expenses	2.99	2.99	3.46	8.93	10.34	13.88
	(g) Other Expenditure	15.00	17.82	21.40	51.38	75.23	112.64
	<b>Total expenses</b>	<b>237.74</b>	<b>309.61</b>	<b>404.26</b>	<b>580.74</b>	<b>678.28</b>	<b>1,465.33</b>
3	<b>Profit before exceptional items and tax</b>	<b>77.36</b>	<b>27.66</b>	<b>(9.60)</b>	<b>89.82</b>	<b>(52.08)</b>	<b>(58.11)</b>
4	Exceptional items	-	-	-	-	-	-
5	<b>Profit/ (Loss) before tax</b>	<b>77.36</b>	<b>27.66</b>	<b>(9.60)</b>	<b>89.82</b>	<b>(52.08)</b>	<b>(58.11)</b>
6	<b>Tax Expense</b>						
	(a) Current tax	10.64	-	(0.00)	10.42	0.02	(0.75)
	(b) Deferred tax	7.25	7.30	(2.42)	10.49	(12.98)	(12.66)
	<b>Total tax expenses</b>	<b>17.89</b>	<b>7.30</b>	<b>(2.42)</b>	<b>20.91</b>	<b>(12.96)</b>	<b>(13.41)</b>
7	<b>Net Profit/ (Loss) for the period</b>	<b>59.47</b>	<b>20.36</b>	<b>(7.18)</b>	<b>68.91</b>	<b>(39.12)</b>	<b>(44.70)</b>
8	<b>Other Comprehensive Income (Net of Taxes)</b>						
	(A)(i). Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	(B)(i). Item that will not be reclassified to profit or loss	3.51	(0.36)	0.43	4.83	(0.52)	(2.34)
	(ii). Income tax relating to items that will not be reclassified to profit or loss	(0.88)	0.09	(0.11)	(1.21)	0.13	0.59
	<b>Total other Comprehensive Income (net of taxes)</b>	<b>2.63</b>	<b>(0.27)</b>	<b>0.32</b>	<b>3.62</b>	<b>(0.39)</b>	<b>(1.75)</b>
9	<b>Total Comprehensive Income for the period</b>	<b>62.10</b>	<b>20.09</b>	<b>(6.85)</b>	<b>72.53</b>	<b>(39.50)</b>	<b>(46.45)</b>
10	<b>Paid-up equity share capital (Face Value of ₹ 10/- per share)</b>	<b>24.50</b>	<b>24.50</b>	<b>24.50</b>	<b>24.50</b>	<b>24.50</b>	<b>24.50</b>
11	<b>Other equity as per Balance Sheet of previous accounting year</b>						<b>1,146.69</b>
12	<b>Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)</b>						
	<b>Basic /Diluted EPS (in Rs.)</b>	<b>24.27</b>	<b>8.31</b>	<b>(2.93)</b>	<b>28.13</b>	<b>(15.97)</b>	<b>(18.25)</b>



*[Handwritten signature]*

**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544

**Notes:**

- 1) The above Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.02.2022.
- 2) The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
- 5) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 6) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA  
DIRECTOR & CEO  
DIN : 00312369

Place: Mumbai

Dated: 12th February, 2022





**TRIOCHEM PRODUCTS LIMITED**
**MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS**

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544



<p style="text-align: center;"><b>TRIOCHEM PRODUCTS LIMITED</b>  Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001  website: <a href="http://www.triochemproducts.com">www.triochemproducts.com</a>  CIN: L24249MH1972PLC015544</p>							
(Rs. in lakhs) Except EPS							

**EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021**

Sr	Particulars	Quarter Ended			Nine Months Ended		For the Year Ended 31-Mar-21 Audited
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	315.10	337.27	394.66	670.56	626.20	1,407.22
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	77.36	27.66	(9.60)	89.82	(52.08)	(58.11)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	77.36	27.66	(9.60)	89.82	(52.08)	(58.11)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	59.47	20.36	(7.18)	68.91	(39.12)	(44.70)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income]	2.63	(0.27)	0.32	3.62	(0.39)	(1.75)
6	Equity share capital (Face value Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Other Equity						1,146.69
8	Earnings per share (of Rs.10/- each) (for continuing and discontinued)						
	a) Basic (not annualized)	24.27	8.31	(2.93)	28.13	(15.97)	(18.25)
	b) Diluted (not annualized)	24.27	8.31	(2.93)	28.13	(15.97)	(18.25)

**Notes:**

- 1) The above Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.02.2022.
- 2) The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
- 5) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 6) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 7) The above is an extract of the detailed format of unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website of BSE ([www.bseindia.com](http://www.bseindia.com)) and on the Company's website [www.triochemproducts.com](http://www.triochemproducts.com)

**FOR TRIOCHEM PRODUCTS LIMITED**

Place: Mumbai

Dated: 12th February, 2022



9

**RAMU S. DEORA**  
**DIRECTOR & CEO**  
DIN: 00312369

**BSE LTD**  
**ACKNOWLEDGEMENT**

Acknowledgement No	: 1202202202473633	Date & Time : 12/02/2022 02:47:36 PM
Scrip Code	: 512101	
Entity Name	: Triochem Products Limited	
Compliance Type	: Regulation 33 - Financial Results	
Quarter / Period	: 31/12/2021	
Mode	: E-Filing	